Search Results for 'Nsclc'

Nsclc published presentations and documents on DocSlides.

Immunotherapy in Non-Small Cell Lung Cancer (NSCLC)

Immunotherapy in Non-Small Cell Lung Cancer (NSCLC)

by stefany-barnette

Renato G. Martins, MD, MPH. Medical Director, Tho...

Antiangiogenic Agents in Advanced NSCLC

Antiangiogenic Agents in Advanced NSCLC

by ellena-manuel

Jared Weiss, MD . Assistant . Professor of Medici...

EGFR-Mutated Advanced NSCLC

EGFR-Mutated Advanced NSCLC

by sherrill-nordquist

The Coming Paradigm Shift. Faculty. Suresh S. Ram...

Raising the Bar in the Management of Advanced/Metastatic NSCLC

Raising the Bar in the Management of Advanced/Metastatic NSCLC

by debby-jeon

Dr Tan . Jiunn. Liang. Clinical Specialist (Resp...

SW GLH services for NSCLC – An update

SW GLH services for NSCLC – An update

by everly

Professor Rachel Butler. The genomic complexity of...

NSCLC with high PD-L1 expression on tumor cells or tumor-infiltrating immune cells represents disti

NSCLC with high PD-L1 expression on tumor cells or tumor-infiltrating immune cells represents disti

by sawyer742

Intervista a Federico . Cappuzzo. Background:. Pr...

by luanne-stotts

Brada. . Torino. . 6 March 2015. Perspectives...

MEK Inhibitors and their potential role in relapsed NSCLC

MEK Inhibitors and their potential role in relapsed NSCLC

by debby-jeon

Ranee Mehra, MD. Fox Chase Cancer Center. Philade...

by alida-meadow

Gandara. , MD. University of California, Davis . ...

by cheryl-pisano

Le Chevalier, . MD. The Role of Translational Res...

Using Non-targeted Therapies in Targeted Lung Cancer Popula

Using Non-targeted Therapies in Targeted Lung Cancer Popula

by ellena-manuel

Nathan Pennell, M.D., Ph.D.. September 6, 2014. O...

NSCLC with high PD-L1 expression on tumor cells or tumor-in

NSCLC with high PD-L1 expression on tumor cells or tumor-in

by test

Intervista a Federico . Cappuzzo. Background:. P...

by pasty-toler

MD. The Evolving Treatment Landscape in NSCLC: Co...

by jane-oiler

of the expression of . 17-beta-hydroxysteroid . ...

EGFR-Mutated NSCLC and CNS Involvement: the Conundrum

EGFR-Mutated NSCLC and CNS Involvement: the Conundrum

by pasty-toler

This program will include a discussion of off-lab...

The Role of Antiangiogenic Agents

The Role of Antiangiogenic Agents

by luanne-stotts

The Role of Antiangiogenic Agents in the Changin...

The Cancer genome atlas (TCGA) and the search for a CUP genetic/epigenetic signature

The Cancer genome atlas (TCGA) and the search for a CUP genetic/epigenetic signature

by stefany-barnette

The Cancer genome atlas (TCGA) and the search for...

Please note, these are the

Please note, these are the

by disclaimercanon

actual. . video-recorded proceedings from the . l...

Optimizing Nursing Management of Patients Receiving Novel Therapies for Advanced NSCLC

Optimizing Nursing Management of Patients Receiving Novel Therapies for Advanced NSCLC

by southan

Beth . Eaby. -Sandy, MSN, CRNP, OCN. ®. Nurse Pra...

Please note, these are the actual video-recorded

Please note, these are the actual video-recorded

by chaptoe

proceedings from the live CME event and may includ...

NSCLC: Epidemiology and disease characteristics

NSCLC: Epidemiology and disease characteristics

by scarlett

NSCLC, non-small cell lung cancer.. Lung cancer in...

Beth Sandy, MSN, CRNP Nurse Practitioner

Beth Sandy, MSN, CRNP Nurse Practitioner

by PriceOfFreedom

Abramson Cancer Center . University of Pennsylvani...

Multidisciplinary approach to lung cancer

Multidisciplinary approach to lung cancer

by elena

Kamil Konopka. Department of Oncology, University ...

Treatment in Advanced Non-Small Cell Lung Cancer

Treatment in Advanced Non-Small Cell Lung Cancer

by oconnor

. 5. th. most commonly diagnosed cancer in Austra...

Consensus or Controversy?

Consensus or Controversy?

by okelly

Addressing Practical Clinical Questions Across the...

Integration of Immunotherapy Across

Integration of Immunotherapy Across

by karlyn-bohler

the Spectrum of Lung Cancer. Karen Kelly, MD. Pro...

Slides last updated:

Slides last updated:

by calandra-battersby

October 2013. There are two main types of lung . ...

Lung malignancy

Lung malignancy

by tawny-fly

Dr. Rachel Cary, FY1 Warwick Hospital. Learning ...

Targeting KRAS and down streaming

Targeting KRAS and down streaming

by alexa-scheidler

pathways. Federico Cappuzzo. Istituto Toscano Tum...

by min-jolicoeur

targeted. : . limiti e successi nelle metastasi ...

Detection of Mutations in EGFR in Circulating Lung-Cancer C

Detection of Mutations in EGFR in Circulating Lung-Cancer C

by sherrill-nordquist

Colin Reisterer and Nick Swenson. S. . Maheswaran...

by alida-meadow

treatments. in WT . pts. : . which. . opportuni...

Slides last updated:

Slides last updated:

by stefany-barnette

October 2013 . Ferlay . J, Shin HR, Bray F, Forma...

Integration of Immunotherapy Across

Integration of Immunotherapy Across

by pamella-moone

the Spectrum of Lung Cancer. Karen Kelly, MD. Pro...

Italian cohort of

Italian cohort of

by test

nivolumab. Expanded Access . Programme. (EAP): ...

Minesh Mehta, Northwestern University

Minesh Mehta, Northwestern University

by mitsue-stanley

Chicago, IL. Radiation for Prevention and Treatme...

Optimal treatment for elderly patients with NSCLC

Optimal treatment for elderly patients with NSCLC

by cheryl-pisano

Giorgio V. Scagliotti. University. of . Torino,....

L’algoritmo terapeutico

L’algoritmo terapeutico

by calandra-battersby

attraverso . i . c. asi clinici. Giuseppe . Valma...

Estimated costs of managing treatment-related adverse

Estimated costs of managing treatment-related adverse

by lindy-dunigan

eventsof. . nivolumab. and . docetaxel. in the...

Low TPS High TPS TPS = PD-L1 tumor proportion score Low TPS = 10%; high TPS = 60%

Low TPS High TPS TPS = PD-L1 tumor proportion score Low TPS = 10%; high TPS = 60%

by olivia-moreira

Low TPS High TPS TPS = PD-L1 tumor proportion sco...